Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

British Journal of Cancer

Volumn 90, Issue 10, 2004, Pages 1942-1948

  Stendahl, M ^a   Kronblad, A ^a   Ryden L ^a   Emdin, S ^b   Bengtsson, N O ^b   Landberg, G ^a  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Cyclin D1; Oestrogen receptor; Predictive factors; Tamoxifen

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR; SURVIVAL; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN; UP-REGULATION;

EID: 2942533005     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601831     Document Type: Article

References (25)

1. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112
2. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R (2002) Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86: 580-586
3. Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R (2002) Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 21: 8158-8165
4. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133
5. EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467
6. Elwood IM, Godolphin W (1980) Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 42: 635-644
7. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99
8. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY (2003) Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 10: 141-144
9. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL (2002) Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 62: 6916-6923
10. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS (2003) Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53: 74-80
11. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF (1999) Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5: 2069-2076
12. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME (2000) Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20: 8667-8675
13. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME (1999) P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 96: 5382-5387
14. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73: 728-734
15. Naidu R, Wahab NA, Yadav MM, Kutty MK (2002) Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 9: 409-416
16. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17: 5338-5347
17. Pacilio C, Germano D, Addeo R, Altucci L, Petrizzi VB, Cancemi M, Cicatiello L, Salzano S, Lallemand F, Michalides RJ, Bresciani F, Weisz A (1998) Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res 58: 871-876
18. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA (1995) Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
20. Thorpe SM, Christensen IJ, Rasmussen BB, Rose C (1993) Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 29A: 971-977
21. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP (1997) Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150: 705-711
22. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671
23. Zhou Q, Hopp T, Fuqua SA, Steeg PS (2001) Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett 162: 3-17
24. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R (1998) Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-3498
25. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415